[1]Tomer Y. Mechanisms of autoimmune thyroid diseases: from genetics to epigenetics\[J\]. Annu Rev Pathol,2014,9:147-156.
[2]MartínezHernndez R, SampedroNúez M, SerranoSomavilla A, et al. A MicroRNA signature for evaluation of risk and severity of autoimmune thyroid diseases\[J\]. J Clin Endocrinol Metab,2018,103(3):1139-1150.
[3]Merrill SJ, Minucci SB. Thyroid autoimmunity: an interplay of factors\[J\]. Vitam Horm,2018,106:129-145.
[4]Kabekkodu SP, Shukla V, Varghese VK, et al. Cluster miRNAs and cancer: diagnostic, prognostic and therapeutic opportunities\[J\]. Wiley Interdiscip Rev RNA,2019:e1563.
[5]Mousavi M J, Jamshidi A, Chopra A, et al. Implications of the noncoding RNAs in rheumatoid arthritis pathogenesis\[J\]. J Cell Physiol,2018,234(1):335-347.
[6]Zhao L, Zhou X, Shan X, et al. Differential expression levels of plasma microRNA in Hashimoto′s disease\[J\]. Gene,2018,642:152-158.
[7]Hirahara K, Nakayama T. CD4+ Tcell subsets in inflammatory diseases: beyond the Th1/Th2 paradigm\[J\]. Int Immunol,2016,28(4):163-171.
[8]Safdari V, Alijani E, Nemati M, et al. Imbalances in T cellrelated transcription factors among patients with Hashimoto′s thyroiditis\[J\]. Sultan Qaboos Univ Med J,2017,17(2):e174-e180.
[9]Mokashi P, Khanna A, Pandita N. Flavonoids from enicostema littorale blume enhances glucose uptake of cells in insulin resistant human liver cancer (HepG2) cell line via IRS1/PI3K/Akt pathway\[J\]. Biomed Pharmacother,2017,90:268-277.
[10]Zhao X, Zhu D, Lu C, et al.MicroRNA126 inhibits the migration and invasion of endometrial cancer cells by targeting insulin receptor substrate 1\[J\].Oncol Lett, 2016, 11(2):1207-1212.
[11]SimonSzab L, Kokas M, Greff Z, et al.Novel compounds reducing IRS1 serine phosphorylation for treatment of diabetes\[J\].Bioorg Med Chem Lett, 2016, 26(2):424-428.
[12]Stentz FB, Kitabchi AE. Hyperglycemiainduced activation of human Tlymphocytes with de novo emergence of insulin receptors and generation of reactive oxygen species\[J\]. Biochem Biophys Res Commun,2005,335(2):491-495.
[13]Chu F, Hu Y, Zhou Y, et al. MicroRNA126 deficiency enhanced the activation and function of CD4+ T cells by elevating IRS1 pathway\[J\]. Clin Exp Immunol,2018,191(2):166-179.
[14]Wu W, Xiao H, LagunaFernandez A, et al.Flowdependent regulation of Kruppellike factor 2 is mediated by microRNA92a\[J\].Circulation, 2011, 124(5):633-641.
[15]Rezaei N, Talebi F, Ghorbani S, et al. MicroRNA92a drives Th1 responses in the experimental autoimmune encephalomyelitis\[J\]. Inflammation,2019,42(1):235-245.
[16]Bardua M, Haftmann C, Durek P, et al. MicroRNA31 reduces the motility of proinflammatory T helper 1 lymphocytes\[J\]. Front Immunol,2018,9:2813.
[17]Haftmann C, Stittrich AB, Sgouroudis E, et al. Lymphocyte signaling: regulation of FoxO transcription factors by microRNAs\[J\].Ann N Y Acad Sci, 2012, 1247:46-55.
[18]Li D, Cai W, Gu R, et al. Th17 cell plays a role in the pathogenesis of Hashimoto′s thyroiditis in patients\[J\]. Clin Immunol,2013,149(3):411-420.
[19]Sun XG, Tao JH, Xiang N, et al. Negative correlation between miR326 and Ets1 in regulatory T cells from newonset SLE patients\[J\]. Inflammation,2016,39(2):822-829.
[20]Zhao N, Zou H, Qin J, et al. MicroRNA326 contributes to autoimmune thyroiditis by targeting the Ets1 protein\[J\]. Endocrine,2018,59(1):120-129.
[21]Du C, Liu C, Kang J, et al. MicroRNA miR326 regulates TH17 differentiation and is associated with the pathogenesis of multiple sclerosis\[J\]. Nat Immunol,2009,10(12):1252-1259.
[22]Jang SY, Park SJ, Chae MK, et al. Role of microRNA146a in regulation of fibrosis in orbital fibroblasts from patients with Graves′ orbitopathy\[J\]. Br J Ophthalmol,2018,102(3):407-414.
[23]Zheng L, Zhuang C, Wang X, et al. Serum miR146a, miR155, and miR210 as potential markers of Graves′ disease\[J\]. J Clin Lab Anal,2017,e22266.
[24]Li K, Du Y, Jiang B L, et al. Increased microRNA155 and decreased microRNA146a may promote ocular inflammation and proliferation in Graves′ ophthalmopathy\[J\]. Med Sci Monit,2014,20:639-643.
[25]Wei H, Guan M, Qin Y, et al. Circulating levels of miR146a and IL17 are significantly correlated with the clinical activity of Graves′ ophthalmopathy\[J\]. Endocr J,2014,61(11):1087-1092.
[26]Li B, Wang X, Choi IY, et al. miR146a modulates autoreactive Th17 cell differentiation and regulates organspecific autoimmunity\[J\]. J Clin Invest,2017,127(10):3702-3716.
[27]Wu W, He C, Liu C, et al. miR10a inhibits dendritic cell activation and Th1/Th17 cell immune responses in IBD\[J\]. Gut,2015,64(11):1755-1764.
[28]GonzalezAmaro R, Marazuela M. T regulatory (Treg) and T helper 17 (Th17) lymphocytes in thyroid autoimmunity\[J\]. Endocrine,2016,52(1):30-38.
[29]Safdari V, Alijani E, Nemati M, et al. Imbalances in T cellrelated transcription factors among patients with Hashimoto′s thyroiditis\[J\]. Sultan Qaboos Univ Med J,2017,17(2):e174-e180.
[30]Glick A B, Wodzinski A, Fu P, et al. Impairment of regulatory Tcell function in autoimmune thyroid disease\[J\]. Thyroid,2013,23(7):871-878.
[31]Mao C, Wang S, Xiao Y, et al. Impairment of regulatory capacity of CD4+CD25+ regulatory T cells mediated by dendritic cell polarization and hyperthyroidism in Graves′ disease\[J\]. J Immunol,2011,186(8):4734-4743.
[32]Pan D, Shin YH, Gopalakrishnan G, et al. Regulatory T cells in Graves′ disease\[J\]. Clin Endocrinol (Oxf),2009,71(4):587-593.
[33]Zhao M, Wang LT, Liang GP, et al. Upregulation of microRNA210 induces immune dysfunction via targeting FOXP3 in CD4+ T cells of psoriasis vulgaris\[J\]. Clin Immunol,2014,150(1):22-30.
[34]Hiratsuka I, Yamada H, Munetsuna E, et al. Circulating microRNAs in Graves′ Disease in relation to clinical activity\[J\]. Thyroid,2016,26(10):1431-1440.
[35]Hoye ML, Archambault AS, Gordon TM, et al. MicroRNA signature of central nervous systeminfiltrating dendritic cells in an animal model of multiple sclerosis\[J\]. Immunology,2018,155(1):112-122.
[36]Huang A, Yang Y, Chen S, et al. miR34a promotes DCs development and inhibits their function on T cell activation by targeting WNT1\[J\]. Oncotarget,2017,8(10):17191-17201.
[37]Chen X, Huang F, Qi Y, et al. Serum and thyroid tissue level of let7b and their correlation with TRAb in Graves′ disease\[J\]. J Transl Med,2018,16(1):188.
[38]Chen J, Tian J, Tang X, et al. miR346 regulates CD4+ CXCR5+ T cells in the pathogenesis of Graves′ disease\[J\]. Endocrine,2015,49(3):752-760.
[39]Li J, Cai Y, Sun X, et al. miR346 and TRAb as predicative factors for relapse in Graves′ Disease within ne year\[J\]. Horm Metab Res,2017,49(3):180-184.
[40]Yamada H, Itoh M, Hiratsuka I, et al. Circulating microRNAs in autoimmune thyroid diseases\[J\]. Clin Endocrinol (Oxf),2014,81(2):276-281.
[41]Caselli E, D′Accolti M, Soffritti I, et al. HHV6A in vitro infection of thyrocytes and T cells alters the expression of miRNA associated to autoimmune thyroiditis\[J\]. Virol J,2017,14(1):3.
[42]Qi Y, Zhou Y, Chen X, et al. MicroRNA4443 causes CD4+ T cells dysfunction by targeting TNFRassociated factor 4 in Graves′ disease\[J\]. Front Immunol,2017,8:1440.
[43]Tokic' S, tefanic' M, GlavaObrovac L, et al. miR29a3p/Tbet regulatory circuit is altered in T cells of patients with Hashimoto′s thyroiditis\[J\]. Front Endocrinol (Lausanne),2018,9:264.
[44]Zhu J, Zhang Y, Zhang W, et al. MicroRNA1425p contributes to Hashimoto′s thyroiditis by targeting CLDN1\[J\]. J Transl Med,2016,14(1):166.
[45]ElkoubyNaor L, BenYosef T.Functions of claudin tight junction proteins and their complex interactions in various physiological systems\[J\].Int Rev Cell Mol Biol, 2010, 279:1-32.
[46]Peng H, Liu Y, Tian J, et al. Decreased expression of microRNA125a3p upregulates interleukin23 receptor in patients with Hashimoto′s thyroiditis\[J\]. Immunol Res,2015,62(2):129-136.
[47]Plavec TV, Kucharˇ M, Benko A, et al. Engineered Lactococcus lactis secreting IL23 receptortargeted REX protein blockers for modulation of IL23/Th17mediated inflammation\[J\] .Microorganisms,2019, 7(5). pii: E152.
|